1. Bone A, Guthmann J-P, Nicolau J, et al. Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009–2010: results of a national vaccination campaign. Vaccine 2010; 28(51): 8157–61
2. Afssaps. Résumé des caracteristiques du produit. Panenza® [online]. Available from URL:
http://ansm.sante.fr/var/ansm_site/storage/original/application/104a750b0148a09fe260689d76604aaa.pdf
[Accessed 2012 Aug 6]
3. European Medicines Agency. Summary of product characteristics: Pandemrix®. (EMEA/H/C/000832 -II/0048) [online]. Available from URL:
http://www.ema.europa.eu/docs/fr_FR/document_library/EPAR_-_Product_Information/human/000832/WC500038121.pdf
[Accessed 2010 Oct 21]
4. Haut Conseil de la santé publique. [Guidance on health priority setting for the use of pandemic vaccines against A(H1N1)v influenza virus]. Avis du HCSP du 7 septembre 2009 relatif aux recommandations sur les priorités sanitaires d’utilisation des vaccins pandémiques dirigés contre le virusgrippal A(H1N1)v [in French; online]. HCSP, Paris, 2009. Available from URL:
http://www.sante.gouv.fr/IMG/pdf/Avis_recos_priorites_vaccin._Ah1n1-07-09-09-2.pdf
[Accessed 2012 Aug 6]
5. European Medicines Agency. CHMP recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine [online]. Available from URL:
http://www.emea.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500051739.pdf
[Accessed 2010 Oct 21]